Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
AstraZeneca Prof. Eric YH Chen, MD University of Hong Kong |
---|---|
Information provided by: | AstraZeneca |
ClinicalTrials.gov Identifier: | NCT00334035 |
For schizophrenic patients who remained in remission while on maintenance medication, there may come a point in time when the relative risk for relapse become so low that discontinuation of therapy can be considered. This study is to investigate whether that point in time is reached in 12 months following the first episode illness. Moreover, it also aims to identify other predictors of relapse as well as to evaluate the costs and benefits of maintenance therapy.
Condition | Intervention | Phase |
---|---|---|
Schizophrenia |
Drug: Quetiapine |
Phase IV |
Study Type: | Interventional |
Study Design: | Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Efficacy Study |
Official Title: | Duration of Maintenance Anti-Psychotic Therapy After First -Episode Schizophrenia: a Double-Blind Randomized Placebo-Control Relapse Prevention Study |
Enrollment: | 169 |
Study Start Date: | August 2003 |
Study Completion Date: | June 2007 |
Ages Eligible for Study: | 18 Years to 65 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | D1441C09906 |
Study First Received: | June 2, 2006 |
Last Updated: | June 30, 2008 |
ClinicalTrials.gov Identifier: | NCT00334035 |
Health Authority: | Hong Kong: Department of Health |
Schizophrenia Quetiapine Mental Disorders Psychotic Disorders Schizophrenia and Disorders with Psychotic Features |
Tranquilizing Agents Therapeutic Uses Physiological Effects of Drugs Psychotropic Drugs |
Central Nervous System Depressants Antipsychotic Agents Central Nervous System Agents Pharmacologic Actions |